research Sexual Dysfunction Related to Drugs: a Critical Review. Part V: α-Blocker and 5-ARI Drugs
α-Blockers and 5-ARIs for BPH can cause sexual dysfunction, including erectile and ejaculatory issues.
Search
for
Sort by
Research
90-120 / 1000+ results 
research 1194: The Long Term Effects of Doxazosin, Finasteride, and the Combination on Sexual Function in Men Participating in the MTOPS Study
Doxazosin and finasteride negatively affect sexual function in men with BPH.
research 311 Novel Penile Ultrasound Technique to Explain Mechanism of Erectile Dysfunction (ED) in Young Patients using Finasteride for Androgenic Alopecia
Ultrasound shows 96% of young men with erectile dysfunction after using finasteride have abnormal penile tissue.
research Wider clinical applications of fumaric acid esters: A useful option in psoriasis patients with multiple sclerosis
Finasteride for hair loss in young men may significantly increase the risk of sexual dysfunction.
research Sexual Medicine Reviews—The Premiere Review Journal for the Field of Sexual Medicine
Current treatments for recurrent ischemic priapism are not well-defined and need more research.
research The urologic impact of long-term finasteride 1-mg use for androgenic alopecia: a matched-cohort database analysis
Long-term finasteride use may lead to earlier use of ED medication and lower prostate cancer diagnosis rates.
research IP28-24 RISK OF ERECTILE DYSFUNCTION AMONG REPRODUCTIVE-AGED MEN FOLLOWING LOW-DOSE FINASTERIDE USE FOR ANDROGENETIC ALOPECIA: A PROPENSITY-MATCHED COHORT STUDY
Low-dose finasteride may increase erectile dysfunction risk over time.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
These medications for BPH have known risks and may have new side effects.
research MP11-05 THE UROLOGIC IMPACT OF LONG-TERM FINASTERIDE-1 MG USE FOR ANDROGENIC ALOPECIA: A MATCHED-COHORT DATABASE ANALYSIS
Long-term finasteride use may lower prostate cancer risk but increase the need for erectile dysfunction medication.
research Study of QuantiFERON’S conversion/reversal phenomena in patients with psoriasis during biological treatment
Young men taking finasteride for hair loss have a higher risk of sexual dysfunction.
research The Princeton III Consensus Recommendations for the Management of Erectile Dysfunction and Cardiovascular Disease
The Princeton III Consensus recommends assessing cardiovascular risk in men with erectile dysfunction and prioritizing heart health before treating ED, especially in those with potential heart disease.
research Faculty Opinions recommendation of Treatment of recurrent priapism in sickle cell anemia with finasteride: a new approach.
Finasteride may be a promising treatment for recurrent priapism in sickle cell anemia.
research Evaluation of risk of SSRI-associated impotence and low libido in men exposed to finasteride
Finasteride and SSRIs together increase impotence and low libido risk in men.
research Organic Causes of Erectile Dysfunction in Men Under 40
Many men under 40 with erectile dysfunction have organic causes like vascular issues, medication side effects, or hormonal problems.
research Patient-convenient Long-term Alopecia Treatment via PLGA Microsphere-Loaded Candlelit Microneedle
The new microneedle treatment could be a more effective and convenient option for hair loss.
research Most recent findings of curative drugs for lower urinary tract symptoms in clinical practice
Current treatments for lower urinary tract symptoms include α1-blockers, 5ARIs, PDE5 inhibitors, anticholinergic agents, and β3-adrenergic receptor agonists.
research Pharmacological Approaches in Managing Symptomatic Relief of Benign Prostatic Hyperplasia: A Comprehensive Review
Tadalafil is effective for treating urinary symptoms in men with BPH.
research Lower urinary tract symptoms (LUTS): The role of medications in improvement of quality of life
Medications improve quality of life for men with lower urinary tract symptoms.
research 1153 ERECTILE HEMODYNAMICS ASSESSMENT IN MEN WITH PERSISTENT ERECTILE DYSFUNCTION AFTER 5-ALPHA REDUCTASE INHIBITOR USE
Persistent ED in Propecia users is not due to abnormal blood flow.
research Androgen-induced norepinephrine release in male accessory sex organ smooth muscle growth and differentiation
Androgens increase norepinephrine release, promoting smooth muscle growth in male sex organs, which may contribute to benign prostatic hypertrophy.
research 5α-reductase activity in the prostate
Blocking the enzyme 5α-reductase can shrink the prostate and help treat enlarged prostate issues.
research PNU 157706, a novel dual type I and II5α-reductase inhibitor
PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
research MP45-10 HISTOMORPHOMETRICAL EVALUATION OF THE CORPUS CAVERNOSUM OF HYPERTENSIVE RATS TREATED WITH 5-?-REDUCTASE INHIBITORS
SHH protein helps nerve regeneration in hypertensive rats.
research PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
Tadalafil may reduce the risk of major heart events and blood clots in men with urinary symptoms.
research Methylated CpG dinucleotides in 5-α reductase 2 gene might explain the finasteride-resistance in BPE patients
Methylated gene parts may cause finasteride-resistance in some enlarged prostate patients.
research FINASTERIDE INFLUENCE ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY
Finasteride increases P-glycoprotein activity in the liver and kidney.
research HP-01-004 Histomorphometrical Evaluation of The Corpus Cavernosum of Hypertensive Rats Treated with 5-Alpha-Reductase Inhibitors
5-alpha-reductase inhibitors significantly affect the penile tissue of hypertensive rats.
research The prevention of benign prostatic hyperplasia (bph)
A vaccine may prevent benign prostatic hyperplasia (BPH).
research Abstract 5561: 20(S)-Protopanaxadiol-aglycone downregulates full-length and ligand-independent splice variants of androgen receptor
20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.